The Role of Bcl-2 and Beclin-1 Complex in “Switching” between Apoptosis and Autophagy in Human Glioma Cells upon LY294002 and Sorafenib Treatment

Cells, Journal Year: 2023, Volume and Issue: 12(23), P. 2670 - 2670

Published: Nov. 21, 2023

Background: Gliomas are the most malignant tumors of central nervous system. One factors in their high drug resistance is avoiding programmed death (PCD) induction. This related to overexpression intracellular survival pathways: PI3K-Akt/PKB-mTOR and Ras-Raf-MEK-ERK. Apoptosis autophagy co-existing processes due interactions between Bcl-2 beclin-1 proteins. Their complex may be a molecular “toggle-switch” PCD types. The aim this research was investigate role Bcl-2:beclin-1 glioma cell elimination through combined action LY294002 sorafenib. Methods: Drug cytotoxicity estimated with an MTT test. type evaluated using variant microscopy techniques (fluorochrome staining, immunocytochemistry, transmission electron microscopy), as well formation protein localization. Molecular analysis indicators conducted immunoblotting, immunoprecipitation, ELISA testing. SiRNA used block expression. Results: results showed inhibitors simultaneous application resulted apoptosis becoming dominant. accompanied by changes location tested Conclusions: “Switching” PI3K Raf opens new therapeutic perspectives against gliomas.

Language: Английский

---

E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression

Oncogene, Journal Year: 2023, Volume and Issue: 42(16), P. 1308 - 1320

Published: March 7, 2023

Language: Английский

---

Racial and socioeconomic disparities in glioblastoma outcomes: A single‐center, retrospective cohort study

Cancer, Journal Year: 2023, Volume and Issue: 129(19), P. 3010 - 3022

Published: May 28, 2023

Abstract Background Glioblastoma (GBM) is the most common malignant primary brain tumor. Emerging reports have suggested that racial and socioeconomic disparities influence outcomes of patients with GBM. No studies to date investigated these controlling for isocitrate dehydrogenase (IDH) mutation O‐6‐methylguanine‐DNA methyltransferase (MGMT) status. Methods Adult GBM were retrospectively reviewed at a single institution from 2008 2019. Univariable multivariable complete survival analyses performed. A Cox proportional hazards model was used assess effect race status priori selected variables known relevance survival. Results In total, 995 met inclusion criteria. Of these, 117 (11.7%) African American (AA). The median overall entire cohort 14.23 months. model, AA had better compared White (hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.2–0.69). observed difference significant in both case analysis multiple imputations accounting missing molecular data treatment low income (HR, 2.17; CI, 1.04–4.50), public insurance 2.25; 1.04–4.87), or no 15.63; 2.72–89.67) worse income, insurance, respectively. Conclusions Significant identified after treatment, genetic profile, other associated Overall, demonstrated These findings may suggest possibility protective advantage patients. Plain Language Summary To best personalize understand causes glioblastoma, influences must be examined. authors report their experience O’Neal Comprehensive Cancer Center deep south. this report, contemporary diagnostic are included. conclude there glioblastoma outcome do better.

Language: Английский

---

MUC17 mutations and methylation are associated with poor prognosis in adult-type diffuse glioma patients

Journal of the Neurological Sciences, Journal Year: 2023, Volume and Issue: 452, P. 120762 - 120762

Published: Aug. 2, 2023

Language: Английский

---

Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas

Clinical Neuroradiology, Journal Year: 2024, Volume and Issue: 34(1), P. 33 - 43

Published: Jan. 26, 2024

Language: Английский

---